GRI Bio Investor Relations Material
Latest events
Q1 2025
15 May, 2025
Q4 2024
14 Mar, 2025
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from GRI Bio Inc
Access all reports
GRI Bio Inc. is a biotechnology company focused on developing therapies for inflammatory, fibrotic, and autoimmune diseases. The company specializes in modulating natural killer T (NKT) cells to target immune system dysregulation. Its research and development efforts aim to advance novel small-molecule drug candidates for conditions with high unmet medical needs. The company is headquartered in La Jolla, California, and its shares are listed on the NASDAQ.
Key slides for GRI Bio Inc
Corporate Presentation
GRI Bio Inc
Corporate Presentation
GRI Bio Inc
Latest articles
)
The Fifteenth Generation: A Conversation with Pietro Gussalli Beretta
An interview with Pietro Gussalli Beretta on how Beretta Holding blends 500 years of tradition with global growth, innovation, and long-term vision.
10 Jul 2025
)
Citadel: Relentless Optimization at Global Scale
From a Harvard dorm to global dominance, this is the story of how Ken Griffin created one of the best-performing hedge funds of all time.
4 Jul 2025
)
David A. Ricks: Eli Lilly's Chairman and CEO
David Ricks built a decades-long career at Eli Lilly, now leading the giant company through a defining moment in its long pharmaceutical history.
3 Jul 2025
Ticker symbol
GRI
Country
🇺🇸 United States